Loading clinical trials...
Loading clinical trials...
A Randomized, Eight-week Double-blind, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of the Combination of Aliskiren / Amlodipine (300/5 mg and 300/10 mg) in Comparison With Aliskiren 300 mg in Patients With Essential Hypertension Not Adequately Responsive to Aliskiren 300 mg Monotherapy
Conditions
Interventions
Aliskiren 300 mg
Aliskiren/Amlodipine 300/5 mg
+3 more
Locations
9
Estonia
Investigative site
Estonia, Estonia
Investigative site
France, France
Investigative Site
Iceland, Iceland
Investigative Site
India, India
Investigative site
Italy, Italy
Investigative Site
Lithuania, Lithuania
Start Date
October 1, 2008
Primary Completion Date
May 1, 2009
Completion Date
May 1, 2009
Last Updated
July 12, 2011
NCT02417740
NCT07480265
NCT07073820
NCT06876233
NCT06062394
NCT06899815
Lead Sponsor
Novartis
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions